良性前立腺肥大症（BPH）薬の世界市場 2020年：メーカー別、地域別、種類・用途別

• 英文タイトル：Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-01532 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、105ページ • 納品方法：Eメール • 産業分類：医薬品・治療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、良性前立腺肥大症（BPH）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。良性前立腺肥大症（BPH）薬の種類別市場規模（アルファブロッカー、ホスホジエステラーゼ5型阻害剤、その他）、用途別市場規模（病院、ドラッグストア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Eli Lilly、TEVA、Sanofi、GlaxoSmithKline、Allergan、Astellas Pharma、Novartis、Abbott、Pfizer、Mylan、Merck ・地域別グローバル市場分析 2015年-2020年 ・良性前立腺肥大症（BPH）薬の北米市場（アメリカ、カナダ、メキシコ） ・良性前立腺肥大症（BPH）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・良性前立腺肥大症（BPH）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・良性前立腺肥大症（BPH）薬の南米市場（ブラジル、アルゼンチン） ・良性前立腺肥大症（BPH）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アルファブロッカー、ホスホジエステラーゼ5型阻害剤、その他 ・用途別分析：病院、ドラッグストア、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The Benign Prostatic Hyperplasia (BPH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Benign Prostatic Hyperplasia (BPH) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.9%% in the forecast period of 2020 to 2025 and will expected to reach USD 3540.4 million by 2025, from USD 3417.1 million in 2019.

Market segmentation
Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Benign Prostatic Hyperplasia (BPH) Drugs market has been segmented into
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

By Application, Benign Prostatic Hyperplasia (BPH) Drugs has been segmented into:
Hospitals
Drugstores
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Benign Prostatic Hyperplasia (BPH) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Benign Prostatic Hyperplasia (BPH) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Benign Prostatic Hyperplasia (BPH) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Benign Prostatic Hyperplasia (BPH) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Benign Prostatic Hyperplasia (BPH) Drugs Market Share Analysis
Benign Prostatic Hyperplasia (BPH) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Benign Prostatic Hyperplasia (BPH) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Benign Prostatic Hyperplasia (BPH) Drugs are:
Eli Lilly
TEVA
Sanofi
GlaxoSmithKline
Allergan
Astellas Pharma
Novartis
Abbott
Pfizer
Mylan
Merck

Among other players domestic and global, Benign Prostatic Hyperplasia (BPH) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Drugs in 2018 and 2019.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Overview of Global Benign Prostatic Hyperplasia (BPH) Drugs Market
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly SWOT Analysis
2.1.4 Eli Lilly Product and Services
2.1.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 TEVA
2.2.1 TEVA Details
2.2.2 TEVA Major Business
2.2.3 TEVA SWOT Analysis
2.2.4 TEVA Product and Services
2.2.5 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Allergan
2.5.1 Allergan Details
2.5.2 Allergan Major Business
2.5.3 Allergan SWOT Analysis
2.5.4 Allergan Product and Services
2.5.5 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Astellas Pharma
2.6.1 Astellas Pharma Details
2.6.2 Astellas Pharma Major Business
2.6.3 Astellas Pharma Product and Services
2.6.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Product and Services
2.7.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Abbott
2.8.1 Abbott Details
2.8.2 Abbott Major Business
2.8.3 Abbott Product and Services
2.8.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Product and Services
2.9.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Mylan
2.10.1 Mylan Details
2.10.2 Mylan Major Business
2.10.3 Mylan Product and Services
2.10.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Merck
2.11.1 Merck Details
2.11.2 Merck Major Business
2.11.3 Merck Product and Services
2.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
6.3 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
6.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7.5 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2015-2020)
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025)
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2021-2025)
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 9. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 10. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 11. Eli Lilly SWOT Analysis
Table 12. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 13. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. TEVA Basic Information, Manufacturing Base and Competitors
Table 15. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 16. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 17. TEVA SWOT Analysis
Table 18. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 19. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Sanofi Basic Information, Manufacturing Base and Competitors
Table 21. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 22. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 23. Sanofi SWOT Analysis
Table 24. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 25. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 27. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 28. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 29. GlaxoSmithKline SWOT Analysis
Table 30. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 31. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Allergan Basic Information, Manufacturing Base and Competitors
Table 33. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 34. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 35. Allergan SWOT Analysis
Table 36. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 37. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 40. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 41. Astellas Pharma SWOT Analysis
Table 42. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 43. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Novartis Basic Information, Manufacturing Base and Competitors
Table 45. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 46. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 47. Novartis SWOT Analysis
Table 48. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 49. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Abbott Basic Information, Manufacturing Base and Competitors
Table 51. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 52. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 53. Abbott SWOT Analysis
Table 54. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 55. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. Pfizer Basic Information, Manufacturing Base and Competitors
Table 57. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 58. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 59. Pfizer SWOT Analysis
Table 60. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 61. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Mylan Basic Information, Manufacturing Base and Competitors
Table 63. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 64. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 65. Mylan SWOT Analysis
Table 66. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 67. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 68. Merck Basic Information, Manufacturing Base and Competitors
Table 69. Merck Benign Prostatic Hyperplasia (BPH) Drugs Major Business
Table 70. Merck Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)
Table 71. Merck SWOT Analysis
Table 72. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 73. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 74. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2018-2019) (M Units)
Table 75. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2015-2020) (M Units)
Table 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2015-2020)
Table 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 79. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)
Table 80. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)
Table 81. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 82. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)
Table 83. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)
Table 84. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)
Table 85. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 86. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2015-2020) (M Units)
Table 87. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2015-2020)
Table 88. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 89. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)
Table 90. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)
Table 91. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 92. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)
Table 93. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)
Table 94. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)
Table 95. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 96. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)
Table 97. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2015-2020) (M Units)
Table 98. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2015-2020)
Table 99. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2015-2020) (USD Million)
Table 100. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)
Table 101. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2015-2020) (M Units)
Table 102. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2015-2020)
Table 103. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions (2021-2025) (M Units)
Table 104. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Regions (2021-2025)
Table 105. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2025) (M Units)
Table 106. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2021-2025)
Table 107. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2025)
Table 108. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2021-2025)
Table 109. Direct Channel Pros & Cons
Table 110. Indirect Channel Pros & Cons
Table 111. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Picture
Figure 2. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2019
Figure 3. Alpha-Blocker Picture
Figure 4. Phosphodiesterase Type-5 Inhibitors Picture
Figure 5. Others Picture
Figure 6. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Drugstores Picture
Figure 9. Others Picture
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2019
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions (2015-2020)
Figure 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2018
Figure 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
Figure 40. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
Figure 42. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020)
Figure 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)
Figure 46. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2018
Figure 47. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2018
Figure 49. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 50. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 51. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2019
Figure 55. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 56. UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 57. France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 58. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 59. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 60. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2019
Figure 63. China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 64. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 65. Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 66. India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 67. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 68. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2019
Figure 70. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2019
Figure 71. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 72. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 73. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 78. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 79. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 80. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2015-2020) (M Units)
Figure 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2021-2025) (M Units)
Figure 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025) (M Units)
Figure 84. Europe Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025) (M Units)
Figure 85. Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025) (M Units)
Figure 86. South America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025) (M Units)
Figure 87. Middle East & Africa Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2021-2025) (M Units)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel

---